QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook
QIAGEN (NYSE:QGEN) reports strong preliminary Q1 2025 results, exceeding previous guidance. Net sales grew approximately 5% (+7% at constant exchange rates) to about $483 million, surpassing the outlook of 3% CER growth.
The company's QuantiFERON latent TB test saw ~15% CER growth, while the QIAstat-Dx syndromic testing system advanced above 35% CER. The QIAcuity digital PCR system and QIAGEN Digital Insights both achieved high-single-digit CER gains. Sample technologies sales declined 1% CER due to cautious instrument spending among Life Sciences customers.
QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to $2.35 CER from $2.28 CER, while maintaining its goal to improve adjusted operating income margin to above 30%. Q1 2025 adjusted diluted EPS is expected to be at least $0.55 CER, exceeding the previous outlook of $0.50 CER.
QIAGEN (NYSE:QGEN) riporta risultati preliminari forti per il primo trimestre del 2025, superando le previsioni precedenti. Le vendite nette sono cresciute di circa 5% (+7% a tassi di cambio costanti) a circa 483 milioni di dollari, superando le aspettative di una crescita del 3% a tassi di cambio costanti.
Il test per la TB latente QuantiFERON ha registrato una crescita di circa il 15% a tassi di cambio costanti, mentre il sistema di test sindromico QIAstat-Dx ha superato il 35% a tassi di cambio costanti. Il sistema di PCR digitale QIAcuity e QIAGEN Digital Insights hanno entrambi ottenuto guadagni a singolo cifra alta a tassi di cambio costanti. Le vendite delle tecnologie di campionamento sono diminuite dell'1% a tassi di cambio costanti a causa di una spesa cauta per strumenti tra i clienti delle Scienze della Vita.
QIAGEN ha alzato le sue previsioni per l'EPS diluito rettificato dell'intero anno 2025 a 2,35 dollari a tassi di cambio costanti da 2,28 dollari a tassi di cambio costanti, mantenendo l'obiettivo di migliorare il margine di reddito operativo rettificato a oltre il 30%. Si prevede che l'EPS diluito rettificato del primo trimestre del 2025 sarà di almeno 0,55 dollari a tassi di cambio costanti, superando le precedenti previsioni di 0,50 dollari a tassi di cambio costanti.
QIAGEN (NYSE:QGEN) informa sobre resultados preliminares sólidos para el primer trimestre de 2025, superando las guías anteriores. Las ventas netas crecieron aproximadamente 5% (+7% a tasas de cambio constantes) hasta cerca de 483 millones de dólares, superando la perspectiva de un crecimiento del 3% a tasas de cambio constantes.
La prueba para la TB latente QuantiFERON experimentó un crecimiento de aproximadamente 15% a tasas de cambio constantes, mientras que el sistema de pruebas sindrómicas QIAstat-Dx avanzó por encima del 35% a tasas de cambio constantes. El sistema de PCR digital QIAcuity y QIAGEN Digital Insights lograron ambos ganancias de un solo dígito alto a tasas de cambio constantes. Las ventas de tecnologías de muestra disminuyeron un 1% a tasas de cambio constantes debido a un gasto cauteloso en instrumentos entre los clientes de Ciencias de la Vida.
QIAGEN ha elevado su pronóstico de EPS diluido ajustado para todo el año 2025 a 2,35 dólares a tasas de cambio constantes desde 2,28 dólares a tasas de cambio constantes, mientras mantiene su objetivo de mejorar el margen de ingresos operativos ajustados por encima del 30%. Se espera que el EPS diluido ajustado del primer trimestre de 2025 sea de al menos 0,55 dólares a tasas de cambio constantes, superando la perspectiva anterior de 0,50 dólares a tasas de cambio constantes.
QIAGEN (NYSE:QGEN)은 2025년 1분기 예비 결과를 발표하며 이전 가이드를 초과 달성했다고 보고했습니다. 순매출은 약 5% (+7% 환율 변동 제외) 증가하여 약 4억 8,300만 달러에 달하며, 3% 환율 변동 제외 성장 전망을 초과했습니다.
회사의 QuantiFERON 잠복 결핵 검사에서 약 15% 환율 변동 제외 성장을 보였고, QIAstat-Dx 증후군 검사 시스템은 35% 이상 성장했습니다. QIAcuity 디지털 PCR 시스템과 QIAGEN Digital Insights는 모두 높은 단일 자릿수의 환율 변동 제외 성장을 달성했습니다. 샘플 기술 판매는 생명 과학 고객의 신중한 기기 지출로 인해 1% 환율 변동 제외로 감소했습니다.
QIAGEN은 2025년 전체 연도 조정 후 희석 EPS 전망을 2.35달러 환율 변동 제외로 상향 조정했으며, 2.28달러 환율 변동 제외에서 조정된 운영 수익 마진을 30% 이상으로 개선하려는 목표를 유지하고 있습니다. 2025년 1분기 조정 후 희석 EPS는 최소 0.55달러 환율 변동 제외로 예상되며, 이전 전망인 0.50달러 환율 변동 제외를 초과할 것으로 보입니다.
QIAGEN (NYSE:QGEN) annonce des résultats préliminaires solides pour le premier trimestre 2025, dépassant les prévisions précédentes. Les ventes nettes ont augmenté d'environ 5% (+7% à taux de change constant), atteignant environ 483 millions de dollars, dépassant les prévisions de croissance de 3% à taux de change constant.
Le test QuantiFERON pour la tuberculose latente a enregistré une croissance d'environ 15% à taux de change constant, tandis que le système de test syndromique QIAstat-Dx a progressé de plus de 35% à taux de change constant. Le système de PCR numérique QIAcuity et QIAGEN Digital Insights ont tous deux réalisé des gains à un chiffre élevé à taux de change constant. Les ventes des technologies d'échantillonnage ont diminué de 1% à taux de change constant en raison d'une dépense prudente en instruments parmi les clients des sciences de la vie.
QIAGEN a relevé ses prévisions d'EPS dilué ajusté pour l'année 2025 à 2,35 dollars à taux de change constant contre 2,28 dollars à taux de change constant, tout en maintenant son objectif d'améliorer la marge de bénéfice opérationnel ajusté à plus de 30%. On s'attend à ce que l'EPS dilué ajusté du premier trimestre 2025 soit d'au moins 0,55 dollars à taux de change constant, dépassant l'ancienne prévision de 0,50 dollars à taux de change constant.
QIAGEN (NYSE:QGEN) berichtet über starke vorläufige Ergebnisse für das erste Quartal 2025, die die vorherigen Prognosen übertreffen. Der Nettoumsatz stieg um etwa 5% (+7% bei konstanten Wechselkursen) auf etwa 483 Millionen US-Dollar und übertraf damit die Aussicht auf ein Wachstum von 3% bei konstanten Wechselkursen.
Der QuantiFERON Test auf latente TB verzeichnete ein Wachstum von etwa 15% bei konstanten Wechselkursen, während das syndromische Testsystem QIAstat-Dx um über 35% bei konstanten Wechselkursen zulegte. Das digitale PCR-System QIAcuity und QIAGEN Digital Insights erzielten beide hohe einstellige Zuwächse bei konstanten Wechselkursen. Der Umsatz mit Probentechnologien ging um 1% bei konstanten Wechselkursen zurück, was auf eine vorsichtige Ausgabenhaltung bei den Lebenswissenschaftskunden zurückzuführen ist.
QIAGEN hat seine Prognose für das bereinigte verwässerte EPS für das Gesamtjahr 2025 auf 2,35 USD bei konstanten Wechselkursen von 2,28 USD bei konstanten Wechselkursen angehoben und gleichzeitig das Ziel beibehalten, die bereinigte operative Gewinnmarge auf über 30% zu verbessern. Für das erste Quartal 2025 wird ein bereinigtes verwässertes EPS von mindestens 0,55 USD bei konstanten Wechselkursen erwartet, was die vorherige Prognose von 0,50 USD bei konstanten Wechselkursen übertrifft.
- Q1 2025 net sales grew 7% CER to $483 million, exceeding guidance
- QuantiFERON TB test sales increased 15% CER
- QIAstat-Dx system sales grew over 35% CER
- Raised full-year 2025 EPS guidance to $2.35 CER from $2.28 CER
- Q1 2025 adjusted EPS of $0.55 CER exceeded previous $0.50 CER outlook
- Sample technologies sales declined 1% CER due to reduced Life Sciences customer spending
- Expected headwinds from new U.S. import tariffs
Insights
QIAGEN's preliminary Q1 2025 results demonstrate exceptional execution across multiple product lines, significantly outperforming their previously communicated outlook. The company achieved
The adjusted EPS of at least
QIAGEN's performance reveals an important dynamic within their portfolio diversification strategy. While sample technologies declined slightly (
Particularly impressive is management's ability to maintain their target of >30% adjusted operating income margin for 2025 despite newly announced U.S. import tariffs. This suggests effective cost management and potential pricing power. The mention of a better-than-expected tax environment also indicates favorable structural conditions supporting profitability.
QIAGEN's Q1 results highlight an accelerating adoption curve for their advanced diagnostic technologies. The
The QIAstat-Dx system's
QIAcuity's high-single-digit growth shows digital PCR technology continuing to gain traction in both research and clinical settings. This technology provides superior sensitivity and precision for applications like liquid biopsy and gene expression analysis, where absolute quantification is critical.
The strength across QIAGEN's diagnostic portfolio indicates healthcare providers are increasingly valuing molecular diagnostic technologies that deliver faster, more accurate results across multiple conditions simultaneously. The company's ability to maintain growth momentum despite cautious spending in the life sciences sector demonstrates the resilience of clinical diagnostic demand and the strategic value of QIAGEN's balanced portfolio approach between research and clinical applications.
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook
VENLO, THE NETHERLANDS / ACCESS Newswire / April 6, 2025 / QIAGEN N.V. (NYSE:QGEN)(Frankfurt Prime Standard:QIA) announces preliminary Q1 2025 results that exceed the outlook for both net sales and adjusted earnings per share (EPS), and also updates its adjusted EPS outlook for full-year 2025, reflecting strong performances across many growth drivers.
Net sales grew approximately
Sales of the QuantiFERON latent TB test grew about
Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.
Full-year 2025, adjusted diluted EPS are now expected to be about
QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
ISIN: NL0015002CX3
Frankfurt Stock Exchange, Regulated Market (Prime Standard)
Contacts QIAGEN N.V.:
John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com
End of Inside Information
SOURCE: QIAGEN N.V.
View the original press release on ACCESS Newswire
FAQ
What is QIAGEN's Q1 2025 revenue growth and total sales?
How much did QIAGEN raise its 2025 EPS guidance?
What was the growth rate of QIAGEN's QuantiFERON TB test in Q1 2025?
How did QIAGEN's QIAstat-Dx system perform in Q1 2025?
What challenges is QIAGEN facing in 2025?
